This is a $149,747,956 definitive cost-no-fee contract awarded by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to the Albert B. Sabin Vaccine Institute, Inc. to advance the development of monovalent vaccines for the prevention of Marburg virus (MARV) and Sudan ebolavirus (SUDV) disease. The contract has an ultimate completion date of September 30, 2026 and was awarded on September 26, 2019. This effort is part of BARDA's Broad Agency Announcement soliciting proposals for the advanced research and development of medical countermeasures against chemical, biological, radiological, nuclear, and pandemic influenza threats. The contract does not have a set-aside designation.
Generated 12/6/24, 9:24 AM